Please use this identifier to cite or link to this item:
https://doi.org/10.2147/OPTH.S47424
DC Field | Value | |
---|---|---|
dc.title | Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema | |
dc.contributor.author | O'Day, R. | |
dc.contributor.author | Barthelmes, D. | |
dc.contributor.author | Zhu, M. | |
dc.contributor.author | Wong, T.Y. | |
dc.contributor.author | McAllister, I.L. | |
dc.contributor.author | Arnold, J.J. | |
dc.contributor.author | Gillies, M.C. | |
dc.date.accessioned | 2014-11-26T07:43:11Z | |
dc.date.available | 2014-11-26T07:43:11Z | |
dc.date.issued | 2013-08-01 | |
dc.identifier.citation | O'Day, R., Barthelmes, D., Zhu, M., Wong, T.Y., McAllister, I.L., Arnold, J.J., Gillies, M.C. (2013-08-01). Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema. Clinical Ophthalmology 7 : 1565-1570. ScholarBank@NUS Repository. https://doi.org/10.2147/OPTH.S47424 | |
dc.identifier.issn | 11775467 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/109214 | |
dc.description.abstract | Purpose: To identify baseline characteristics that predict the number of treatments with intravitreal triamcinolone acetonide (IVTA) plus laser photocoagulation needed to treat diabetic macular edema over a 2-year period. Methods: Individual data from 42 eyes of 42 participants treated with IVTA plus laser photocoagulation for diabetic macular edema during a prospective, randomized, double-masked, placebo-controlled trial were used for this post hoc analysis. Baseline characteristics - age, gender, best-corrected visual acuity, glycosylated hemoglobin, phakic status, intraocular pressure, and central macular thickness (CMT) - were correlated with the number of IVTA plus laser treatments received during the 2 years of this study. Results: The median number of treatments received over the 2-year period was 2.5 (interquartile range 1.0-3.0), with 21 (50%) eyes needing three or more treatments. Eyes that received more IVTA plus laser treatments had a higher mean baseline CMT and eyes with a higher baseline CMT were more likely to receive three or more treatments (odds ratio 5.13, 95% confidence interval 1.75-15.04, P=0.003 per 100 μm increase in CMT). No significant relationship was found between other baseline characteristics and the number of IVTA plus laser treatments received. Conclusion: Higher baseline CMT was strongly linked with receiving more IVTA plus laser treatments. These patients may be at higher risk of developing dose-dependent steroid-related adverse events, cataract progression, and intraocular pressure rise. © 2013 O'Day et al, publisher and licensee Dove Medical Press Ltd. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.2147/OPTH.S47424 | |
dc.source | Scopus | |
dc.subject | Central macular thickness | |
dc.subject | Diabetic macular edema | |
dc.subject | Intravitreal triamcinolone | |
dc.type | Article | |
dc.contributor.department | OPHTHALMOLOGY | |
dc.description.doi | 10.2147/OPTH.S47424 | |
dc.description.sourcetitle | Clinical Ophthalmology | |
dc.description.volume | 7 | |
dc.description.page | 1565-1570 | |
dc.identifier.isiut | 000215966300240 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
2013-baseline_central_macular_thickness_predicts-pub.pdf | 212.1 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.